Drug reviews

2026 Oregon PDAB drug reviews

Archive drug review

2025

Drug review document	Meeting video	Meeting minutes
Vraylar, Entresto, Ajovy, Emgality, Nurtec, Ubrelvy	July 16, 2025	July 16, 2025
Trelegy, Eliquis, Xarelto, Cosentyx, Creon	Aug. 20, 2025	Aug. 20, 2025
Jardiance, Mounjaro, Ozempic, Rybelsus, Trulicity	Sept. 17, 2025	Sept. 17, 2025
Insulin products Basaglar KwikPen, Insulin Glargine-yfgn, Lantus, Lantus SoloStar, Semglee, Toujeo Max SoloStar, Toujeo SoloStar	Oct. 15, 2025	Oct. 15, 2025

About Oregon PDAB drug reviews: The Prescription Drug Affordability Board conducts annual drug reviews for identified prescription drugs as directed by ORS 646A.694 using criteria established in OAR 925.200.0010 and OAR 925.200.0020.

In the drug reviews, the board narrows a list of prescription drugs to a subset list, reviews each drug and applies criteria to determine whether the drugs may cause affordability challenges for Oregonians and health care systems in the state. The board submits a list of up to nine prescription drugs to the Oregon Legislature. Identifying insulin products is optional. Data for the reviews comes from the Drug Price Transparency (DPT) program pursuant to ORS 646A.694, the Oregon Health Authority All Claims All Payers (APAC) data base, and information submitted by insurance carriers through a data call by Oregon Department of Consumer Business Services.